ImmunotiX 500 60 C

ImmunotiX 500 60 C by Xymogen

ImmunotiX 500 60 capsules is an immunity support supplement formulated by Xymogen, which uses only highly-researched ingredients.* This product contains whole glucan particles carefully purified from Saccharomyces cerevisiae (baker’s yeast).* Thanks to this, ImmunotiX 500 60c is of extraordinary quality and may have increased efficacy when compared to similar dietary supplements.*

Who Should Consider ImmunotiX 500 60c by Xymogen?

ImmunotiX 500 60 capsules may support your health if you:

• want to improve your immunity during the cold or flu seasons*
• prefer natural, non-GMO, hypoallergenic supplements*

How May ImmunotiX 500 60 Capsules Support Your Health?

ImmunotiX 500 60c may:

• support your immune function*
• improve your immunity to seasonal challenges*
• promote hematopoiesis following radiation and other bone marrow insult*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about ImmunotiX 500 60c by Xymogen.

Recommendation:
Take one capsule daily, first thing in the morning or last thing at night (before or well after a meal), with a full 8 oz glass of water. 

Serving Size: 1 Capsule
Servings Per Container: 60

Amount Per Serving:
Whole Glucan Particle (providing beta-glucan naturally derived from Saccharomyces cerevisiae)S1 500 mg

Other Ingredients: Dicalcium phosphate dihydrate, capsule (hypromellose and water), magnesium stearate, silica, and medium-chain triglyceride oil.

Does not Contain: Wheat, gluten, corn, yeast protein, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, artificial colors, artificial sweeteners, or preservatives.

Cautions: 
Consult your healthcare practitioner before using ImmunotiX 250. Keep out of reach of children. Avoid if allergic to any ingredient.

Storage:
Keep ImmunotiX 250 tightly closed in a cool, dry place.

Trademarks:
* The statements have not been evaluated by the Food and Drug Administration.

Products listed are not intended to diagnose, treat, cure, or prevent disease.
© 2012 2014 XYMOGEN®

Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

1. Driscoll, M., Hansen, R., Ding, C., et al. (2009). Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biology & Therapy, 8(3), 218–225. https://doi.org/10.4161/cbt.8.3.7904
2. Feldman, S., Schwartz, H. I., Kalman, D. S., et al. (2009). Randomized phase II clinical trials of Wellmune WGP® for immune support during cold and flu season. Journal of Applied Research, 9(1&2), 30–42. Retrieved from http://jrnlappliedresearch.com/articles/Vol9Iss1/FeldmanVol9No1.pdf
3. Kournikakis, B., Mandeville, R., Brousseau, P., et al. (2003). Anthrax-protective effects of yeast beta 1,3 glucans. MedGenMed: Medscape General Medicine, 5(1), 1. [PMID: 12827062]
4. Liang, J., D., Zhang, F., Ding, J., et al. (1998). Enhanced clearance of a multiple antibiotic-resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. International Journal of Immunopharmacology, 20(11), 595–614. [PMID: 9848393]
5. Pelizon, A. C., Kaneno, R., Soares, A. M., et al. (2005). Immunomodulatory activities associated with beta-glucan derived from Saccharomyces cerevisiae. Physiological Research, 54(5), 557–564. [PMID: 16238470]
6. Qi, C., Cai, Y., Gunn, L., et al. (2011). Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood, 117(25), 6825–6836. [PMID: 21531981]
7. Senoglu, N., Yuzbasioglu, M. F., Aral, M., et al. (2008). Protective effects of N-acetylcysteine and beta-glucan pretreatment on oxidative stress in cecal ligation and puncture model of sepsis. Journal of Investigative Surgery, 21(5), 237–243. [PMID: 19160131]
8. Tian, J., Ma, J., Wang, S., et al. (2011). Increased expression of mGITRL on D2SC/1 cells by particulate β-glucan impairs the suppressive effect of CD4(+)CD25(+) regulatory T cells and enhances the effector T cell proliferation. Cell Immunology, 270(2), 183–187. [PMID: 21636079]
9. Turnbull, J. L., Patchen, M. L., & Scadden, D. T. (1999). The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematologica, 102(2), 66–71. [PMID: 10529508]
10. Vetvicka, V. (2011). Glucan-immunostimulant, adjuvant, potential drug. World Journal of Clinical Oncology, 2(2), 115–119. [PMID: 21603320]
11. Vetvicka, V., Terayama, K., Mandeville, R., et al. (2002). Pilot study: Orally-administered yeast β1,3-glucan prophylactically protects against anthrax infection and cancer in mice. Journal of the American Nutraceutical Association, 5(2), 5–9. Retrieved from http://www.ana-jana.org/Journal/journals/JANAVol52.pdf
12. Yan, J., Allendorf, D. J., & Brandley, B. (2005). Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumor monoclonal antibodies to treat cancer. Expert Opinion on Biological Therapy, 5(5), 691–702. [PMID: 15934844]
13. Tsikitis, V., Albina, J., & Reichner, J. (2004). Beta-glucan affects leukocyte navigation in a complex chemotactic ingredient. Surgery, 136(2), 384–389. [PMID: 15300205]